Peter S. Kim Purchases 3,180 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim purchased 3,180 shares of Entrada Therapeutics stock in a transaction dated Monday, March 25th. The shares were bought at an average price of $13.36 per share, with a total value of $42,484.80. Following the completion of the acquisition, the director now directly owns 56,074 shares of the company’s stock, valued at $749,148.64. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Entrada Therapeutics Stock Up 4.3 %

Entrada Therapeutics stock opened at $14.35 on Thursday. Entrada Therapeutics, Inc. has a one year low of $10.62 and a one year high of $18.44. The business’s fifty day moving average is $13.84 and its 200 day moving average is $14.54.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TRDA. BlackRock Inc. increased its position in shares of Entrada Therapeutics by 563.2% during the 2nd quarter. BlackRock Inc. now owns 1,405,806 shares of the company’s stock valued at $21,284,000 after purchasing an additional 1,193,821 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Entrada Therapeutics by 21.9% during the third quarter. Price T Rowe Associates Inc. MD now owns 2,972,050 shares of the company’s stock valued at $46,840,000 after buying an additional 534,552 shares during the last quarter. State Street Corp raised its position in Entrada Therapeutics by 505.8% in the second quarter. State Street Corp now owns 391,191 shares of the company’s stock worth $5,923,000 after acquiring an additional 326,614 shares during the period. Geode Capital Management LLC boosted its stake in shares of Entrada Therapeutics by 118.0% during the 2nd quarter. Geode Capital Management LLC now owns 400,631 shares of the company’s stock worth $6,066,000 after acquiring an additional 216,841 shares during the last quarter. Finally, Nan Fung Group Holdings Ltd bought a new stake in shares of Entrada Therapeutics during the 1st quarter valued at $1,630,000. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on TRDA. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Monday, March 18th. Oppenheimer began coverage on Entrada Therapeutics in a research report on Friday, January 5th. They set an “outperform” rating and a $22.00 price objective on the stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.